320 related articles for article (PubMed ID: 31804851)
1. Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1).
Garg SK; Wernicke-Panten K; Wardecki M; Kramer D; Delalande F; Franek E; Sadeharju K; Monchamp T; Mukherjee B; Shah VN
Diabetes Technol Ther; 2020 Feb; 22(2):85-95. PubMed ID: 31804851
[No Abstract] [Full Text] [Related]
2. Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial.
Garg SK; Wernicke-Panten K; Wardecki M; Kramer D; Delalande F; Franek E; Sadeharju K; Monchamp T; Miossec P; Mukherjee B; Shah VN
Diabetes Technol Ther; 2020 Jul; 22(7):516-526. PubMed ID: 32068436
[No Abstract] [Full Text] [Related]
3. Efficacy, Safety, and Immunogenicity of Insulin Aspart Biosimilar SAR341402 Compared with Originator Insulin Aspart in Adults with Diabetes (GEMELLI 1): A Subgroup Analysis by Prior Type of Mealtime Insulin.
Shah VN; Franek E; Wernicke-Panten K; Pierre S; Mukherjee B; Sadeharju K
Diabetes Ther; 2021 Feb; 12(2):557-568. PubMed ID: 33432547
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic similarity of switching SAR341402 insulin aspart biosimilar and NovoLog insulin aspart versus continuous use of NovoLog in adults with type 1 diabetes: The GEMELLI X trial.
Shah VN; Al-Karadsheh A; Barnes C; Mandry J; Nakhle S; Wernicke-Panten K; Kramer D; Schmider W; Pierre S; Teichert L; Rotthaeuser B; Mukherjee B; Bailey TS
Diabetes Obes Metab; 2024 Feb; 26(2):540-547. PubMed ID: 37880868
[TBL] [Abstract][Full Text] [Related]
5. Safety and Tolerability of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart (NovoLog) When Used in Insulin Pumps in Adults with Type 1 Diabetes: A Randomized, Open-Label Clinical Trial.
Thrasher J; Polsky S; Hovsepian L; Nowotny I; Pierre S; Bois De Fer B; Bhargava A; Mukherjee B; Garg SK
Diabetes Technol Ther; 2020 Sep; 22(9):666-673. PubMed ID: 31833801
[No Abstract] [Full Text] [Related]
6. Safety and Efficacy of Switching SAR341402 Insulin Aspart and Originator Insulin Aspart vs Continuous Use of Originator Insulin Aspart in Adults With Type 1 Diabetes: The GEMELLI X Trial.
Shah VN; Al-Karadsheh A; Barnes C; Mandry J; Nakhle S; Wernicke-Panten K; Kramer D; Schmider W; Pierre S; Teichert L; Rotthaeuser B; Mukherjee B; Bailey TS
J Diabetes Sci Technol; 2024 Feb; ():19322968241232709. PubMed ID: 38420944
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog
Blevins TC; Raiter Y; Sun B; Donnelly C; Shapiro R; Chullikana A; Rao A; Vashishta L; Ranganna G; Barve A
BioDrugs; 2022 Nov; 36(6):761-772. PubMed ID: 36114990
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 1 Diabetes Also Using Insulin Glargine-SORELLA 1 Study.
Garg SK; Wernicke-Panten K; Rojeski M; Pierre S; Kirchhein Y; Jedynasty K
Diabetes Technol Ther; 2017 Sep; 19(9):516-526. PubMed ID: 28722480
[TBL] [Abstract][Full Text] [Related]
9. Comparative assessment of immunogenicity of recombinant insulin Aspart from BioGenomics and its originator NovoRapid® in adult patients with type 2 diabetes mellitus.
Mishra A; Dongre S; Kulkarni G; Deshmane R; Thappa D; Ghade N; Lona J; Kokatam S; Deo A; Sonar S; Krishnan A
J Endocrinol Invest; 2024 Jun; 47(6):1435-1446. PubMed ID: 38147290
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trial.
Hollander PA; Carofano WL; Lam RLH; Golm GT; Eldor R; Crutchlow MF; Marcos MC; Rendell MS; Home PD; Gallwitz B; Rosenstock J
Diabetes Obes Metab; 2018 Sep; 20(9):2229-2237. PubMed ID: 29761615
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trial.
Home PD; Lam RLH; Carofano WL; Golm GT; Eldor R; Crutchlow MF; Marcos MC; Rosenstock J; Hollander PA; Gallwitz B
Diabetes Obes Metab; 2018 Sep; 20(9):2220-2228. PubMed ID: 29766635
[TBL] [Abstract][Full Text] [Related]
12. Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Versus Originator Insulin Aspart Mix 70/30 (NovoMix 30) in People with Diabetes: A 26-Week, Randomized, Open-Label Trial (GEMELLI M).
Aravind SR; Singh KP; Aquitania G; Mogylnytska L; Zalevskaya AG; Matyjaszek-Matuszek B; Wernicke-Panten K; Nguyên-Pascal ML; Pierre S; Rotthaeuser B; Kramer D; Mukherjee B
Diabetes Ther; 2022 May; 13(5):1053-1071. PubMed ID: 35420397
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study.
Christofides EA; Puente O; Norwood P; Denham D; Maheshwari H; Lillestol M; Hart T; Nakhle S; Chadha A; Fitz-Patrick D; Sugimoto D; Soufer J; Young D; Warren M; Huffman D; Reed J; Bays H; Arora S; Rizzardi B; Tidman R; Rendell M; Johnson KA
Diabetes Obes Metab; 2024 Jun; 26(6):2412-2421. PubMed ID: 38558508
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial.
Bode BW; Iotova V; Kovarenko M; Laffel LM; Rao PV; Deenadayalan S; Ekelund M; Larsen SF; Danne T
Diabetes Care; 2019 Jul; 42(7):1255-1262. PubMed ID: 31076415
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 2 Diabetes, Also Using Insulin Glargine: SORELLA 2 Study.
Derwahl KM; Bailey TS; Wernicke-Panten K; Ping L; Pierre S
Diabetes Technol Ther; 2018 Jan; 20(1):49-58. PubMed ID: 29232162
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M): A Subgroup Analysis by Prior Type of Premix Insulin.
Aravind SR; Singh KP; Mogylnytska L; Zalevskaya AG; Matyjaszek-Matuszek B; Wernicke-Panten K; Nguyên-Pascal ML; Pierre S; Rotthaeuser B; Kramer D; Mukherjee B
Diabetes Ther; 2022 Jul; 13(7):1299-1310. PubMed ID: 35650350
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of GP40071 compared with originator insulin aspart (NovoRapid
Karonova TL; Mayorov AY; Magruk MA; Zyangirova ST; Grigoryeva IV; Khmelnitski OK; Myshkovets A; Parfenova TM; Mosikian AA; Drai RV
J Comp Eff Res; 2021 Jun; 10(9):763-775. PubMed ID: 33928797
[No Abstract] [Full Text] [Related]
18. Efficacy and safety of MYL-1501D vs insulin glargine in patients with type 1 diabetes after 52 weeks: Results of the INSTRIDE 1 phase III study.
Blevins TC; Barve A; Sun B; Ankersen M
Diabetes Obes Metab; 2018 Aug; 20(8):1944-1950. PubMed ID: 29656504
[TBL] [Abstract][Full Text] [Related]
19. Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes.
Home P; Derwahl KM; Ziemen M; Wernicke-Panten K; Pierre S; Kirchhein Y; Garg SK
Diabetes Technol Ther; 2018 Feb; 20(2):160-170. PubMed ID: 29355435
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study.
Blevins TC; Dahl D; Rosenstock J; Ilag LL; Huster WJ; Zielonka JS; Pollom RK; Prince MJ
Diabetes Obes Metab; 2015 Aug; 17(8):726-33. PubMed ID: 25974640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
